Defining the HIV pre-exposure prophylaxis care continuum by Nunn, Amy S. et al.
brought to you by COREView metadata, citation and similar papers at core.ac.uk
 Carolina Digital Repository
VIEWPOINT
provided byDefining the HIV pre-exposure prophylaxis
care continuum
Amy S. Nunna,b,c, Lauren Brinkley-Rubinsteind,e,
Catherine E. Oldenburgf, Kenneth H. Mayerg,h, Matthew Mimiagaa,












of the Creative Com
share the work provPre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy. There is little
scientific consensus about how to measure PrEP program implementation progress. We
draw on several years of experience in implementing PrEP programs and propose a PrEP
continuum of care that includes: (1) identifying individuals at highest risk for contracting
HIV, (2) increasing HIV risk awareness among those individuals, (3) enhancing PrEP
awareness, (4) facilitating PrEP access, (5) linking to PrEP care, (6) prescribing PrEP, (7)
initiating PrEP, (8) adhering to PrEP, and (9) retaining individuals in PrEP care. We also
propose four distinct categories of PrEP retention in care that include being: (1)
indicated for PrEP and retained in PrEP care, (2) indicated for PrEP and not retained
in PrEP care, (3) no longer indicated for PrEP, and (4) lost to follow-up for PrEP care. This
continuum of PrEP care creates a framework that researchers and practitioners can use
to measure PrEP awareness, uptake, adherence, and retention. Understanding each
point along the proposed continuum of PrEP care is critical for developing effective PrEP
interventions and for measuring public health progress in PrEP program implementa-
tion. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31:731–734Keywords: HIV prevention, linkage to care, pre-exposure prophylaxis, retention
in carePre-exposure prophylaxis (PrEP) has demonstrated
efficacy in preventing HIV [1–3]. Whereas PrEP use is
expanding globally, there is little consensus about how to
measure progress in PrEP care other than to measure the
number who initiate and adhere to PrEP and then impute
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Fig. 1. The PrEP care continuum. PrEP, pre-exposure prophylaxis.revisit and expand the framework to assess progress in
PrEP implementation. Therefore, we draw on more than
4 years of PrEP implementation experience [5–10] and
propose a PrEP care continuum that assesses the multiple
steps related to PrEP uptake, adherence, and retention
in care.
Because PrEP is intended to reduce HIV acquisition
rather than treat disease, PrEP-related outcomes differ
from the HIV treatment continuum [11]. We propose
that the PrEP care continuum should include the
following steps:(1) Identifying individuals at highest risk for contracting
HIV(2) Increasing HIV risk awareness among those individuals(3) Enhancing PrEP awareness(4) Facilitating PrEP access(5) Linking to PrEP care(6) Prescribing PrEP(7) Initiating PrEP(8) Adhering to PrEP(9) Retaining individuals in PrEP care (see Fig. 1).The first three steps in the PrEP care continuum focus on
PrEP awareness. Steps 4 to 7 are related to PrEP uptake,
and steps 8 and 9 focus on adherence and retention in
PrEP care. Our experiences implementing PrEP suggest
that each of these steps present opportunities for patients
to continue using PrEP or disengage in care [5–10], and
are important points of intervention.
The first outcome on the PrEP care continuum is
identifying populations most at risk of HIV contraction,
and, therefore, suitable for PrEP, who also understand
their own risk for HIV (step 2). Debate about how many
Americans are suitable candidates for PrEP continues;
however, the Centers for Disease Control and Preventionestimate that 25% of all MSM in the United States may
benefit from PrEP [12]. In the United States, MSM are
most impacted by HIV, and misperception of risk has
impeded PrEP uptake among this group [13,14]. Even
among those who realize they are at risk for HIV,
knowledge about PrEP remains limited [15]; the third
step in the Continuum is therefore PrEP awareness. A
recent study in the Deep South found that among those
accessing PrEP services, only 18% were MSM, even
though this group represented close to 50% of incident
HIV cases [16]. Addressing these awareness challenges
will increase PrEP uptake.
The fourth step in the PrEP care continuum is facilitating
access to PrEP care. In the United States, this involves
scheduling an appointment with a medical provider who
prescribes PrEP and usually requires having health
insurance that covers the cost of clinical care and
medications. Lack of insurance coverage may present
significant barriers to engaging in PrEP care, as
medications and provider fees can create financial barriers
to PrEP uptake [6]. Although industry-sponsored
medication assistance programs may help offset costs of
PrEP, other fees related to provider time and laboratory
monitoring may still not be covered [6]. Moreover, many
regions of the United States do not yet have dedicated
PrEP providers [17].
During the initial PrEP appointment, patients are
educated about PrEP and an assessment is performed
to determine whether PrEP is indicated. Among patients
who have access to PrEP care services, not all patients
present for and link to initial PrEP appointments (the fifth
step), highlighting another opportunity to intervene. The
sixth step is prescribing PrEP medications to those who
meet clinical criteria. At this step, there may be
opportunities to measure disengagement from care when
patients do not fill their PrEP prescriptions. After PrEP
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Fig. 2. The PrEP retention continuum. PrEP, pre-exposure
prophylaxis.has been dispensed, patients can initiate PrEP, which is the
seventh step in the PrEP care continuum.
The eighth step is adherence, which includes consistently
taking PrEP. Previous studies have shown that PrEP
adherence is critical to efficacy [1] and can significantly
reduce the risk of HIV acquisition among those who
adhere [18–20]. The final step of the PrEP Continuum is
retention in PrEP care. Retention in PrEP care poses a
significant barrier to successful implementation of PrEP
programs; some studies suggest that patients who are
retained in PrEP care adhere to their medications [6,18].
However, greater efforts are needed to evaluate and clarify
what is meant by retention in PrEP care. Defining who is
successfully retained in care presents challenges. In
contrast with the HIV care continuum, in which
individuals take HIV medications over their lifetime,
discontinuation of PrEP does not necessarily mean that an
individual is lost to care or at increased risk for HIV. The
term ‘prevention effective adherence’ has been used to
acknowledge HIVacquisition risk may change over time
in accordance with relationship changes or decreased
engagement in risky behaviors [21,22].
‘Retention in care’ has been broadly used to describe
whether patients are maintained in PrEP care; however,
we posit that measuring retention is a complex
phenomenon. Building on the ‘prevention effective
adherence’ concept, we propose four distinct categories
to characterize and measure retention in PrEP care:
indicated for PrEP and retained in PrEP care; indicated
for PrEP and not retained in PrEP care; no longer
indicated for PrEP; and lost to follow-up for PrEP care
(see Fig. 2). Our experiences implementing PrEP
programs suggest that individuals change their behaviors
and sexual partnerships over time [5,6]. Some individuals
may not need PrEP and are not lost to follow-up; rather,they no longer meet clinical criteria for taking PrEP.
Capturing each of these retention-related outcomes is
important for measuring progression through the PrEP
continuum, both for individual patients, and also for
population health metrics.
Understanding how and why patients take up, adhere, and
are retained or disengage from PrEP care is critical for
developing effective PrEP interventions. This proposed
PrEP care continuum has some limitations; for example,
in developing countries where PrEP is not yet
commercially available or provided in public health
systems, patients may never even have opportunities to
advance through the PrEP Care Continuum. Never-
theless, this preliminary effort to define benchmarks for
evaluating the impacts of PrEP programs can be useful for
prioritizing interventions to enhance measures to bench-
mark PrEP-related progress.Acknowledgements
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